133 related articles for article (PubMed ID: 21873163)
1. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
[TBL] [Abstract][Full Text] [Related]
2. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
4. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
Dateoka S; Ohnishi Y; Kakudo K
Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
[TBL] [Abstract][Full Text] [Related]
5. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
6. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant.
Rivetti S; Lauriola M; Voltattorni M; Bianchini M; Martini D; Ceccarelli C; Palmieri A; Mattei G; Franchi M; Ugolini G; Rosati G; Montroni I; Taffurelli M; Solmi R
Int J Immunopathol Pharmacol; 2011; 24(3):639-49. PubMed ID: 21978696
[TBL] [Abstract][Full Text] [Related]
8. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3143-9. PubMed ID: 20871033
[TBL] [Abstract][Full Text] [Related]
9. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
10. HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of
Yotsumoto F; Fukagawa S; Miyata K; Nam SO; Katsuda T; Miyahara D; Odawara T; Manabe S; Ishikawa T; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3825-3831. PubMed ID: 28668882
[TBL] [Abstract][Full Text] [Related]
11. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer.
Yotsumoto F; Oki E; Tokunaga E; Maehara Y; Kuroki M; Miyamoto S
Int J Cancer; 2010 Dec; 127(11):2707-17. PubMed ID: 20499311
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
13. Validity of HB-EGF as Target for Human Neuroblastoma Therapy.
Nam SO; Yotsumoto F; Miyata K; Souzaki R; Taguchi T; Kuroki M; Miyamoto S
Anticancer Res; 2015 Aug; 35(8):4433-40. PubMed ID: 26168483
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
Martarelli D; Pompei P; Mazzoni G
Chemotherapy; 2009; 55(6):425-32. PubMed ID: 19996587
[TBL] [Abstract][Full Text] [Related]
15. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
16. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
17. Heparin-binding epidermal growth factor-like growth factor: a hepatic stellate cell proliferation inducer via ErbB receptors.
Zhang D; Zhang J; Jiang X; Li X; Wang Y; Ma J; Jiang H
J Gastroenterol Hepatol; 2014 Mar; 29(3):623-32. PubMed ID: 24303948
[TBL] [Abstract][Full Text] [Related]
18. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
Yagi H; Yotsumoto F; Miyamoto S
Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
[TBL] [Abstract][Full Text] [Related]
19. Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.
Miyata K; Yotsumoto F; Nam SO; Odawara T; Manabe S; Ishikawa T; Itamochi H; Kigawa J; Takada S; Asahara H; Kuroki M; Miyamoto S
Cancer Med; 2014 Oct; 3(5):1159-69. PubMed ID: 25060396
[TBL] [Abstract][Full Text] [Related]
20. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]